First-mover advantage for Wegovy pill

Novo Nordisk President & CEO Mike Doustdar discusses the recent US approval of Novo Nordisk's Wegovy weight loss pill, the advantage of being the first to market, the availability of the pill, the company's gameplan, and the timeline of the pill's release. Doustdar spoke with Bloomberg's Katie Greifeld.

See omnystudio.com/listener for privacy information.